SCHEMBL29450289

SCHEMBL29450289

O=c1[nH][nH]c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 1/20 1.00
▸ POLB P06746 1/20 0.74
▸ KDM4E B2RXH2 5/20 0.54
▸ PARP1 P09874 2/20 0.54
▸ CA12 O43570 1/20 0.54
▸ CA9 Q16790 1/20 0.54
▸ ALDH1A1 P00352 5/20 0.50
▸ DAO P14920 4/20 0.50
▸ LMNA P02545 2/20 0.50
▸ LIMK1 P53667 2/20 0.50
▸ CLK4 Q9HAZ1 2/20 0.50
▸ GPR3 P46089 2/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ METAP2 P50579 1/20 0.50
▸ CHEK1 O14757 1/20 0.50
▸ AURKA O14965 1/20 0.50
▸ DAPK3 O43293 1/20 0.50
▸ JAK2 O60674 1/20 0.50
▸ PRKD3 O94806 1/20 0.50
▸ MAP4K4 O95819 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL291774 1.00 ALOX5 (1.00) ALOX5POLBKDM4EPARP1CA12
Hydrochloric Acid SCHEMBL18152218 0.97 ALOX5 (0.95) ALOX5POLBKDM4EPARP1CA12
SCHEMBL29349675 0.83 ALOX5 (0.70) ALOX5POLBKDM4EPARP1CA12
SCHEMBL29766 0.83 ALOX5 (0.70) ALOX5POLBKDM4EPARP1CA12
SCHEMBL15621628 0.82 ALOX5 (0.68) ALOX5POLBKDM4EPARP1CA12
SCHEMBL30218500 0.80 ALOX5 (0.67) ALOX5POLBKDM4EPARP1CA12
SCHEMBL31438327 0.80 ALOX5 (0.67) ALOX5POLBKDM4EPARP1CA12
Hydrochloric Acid SCHEMBL6170559 0.80 ALOX5 (0.67) ALOX5POLBKDM4EPARP1CA12
Charcoal, Activated SCHEMBL31491466 0.80 ALOX5 (0.67) ALOX5POLBKDM4EPARP1CA12
SCHEMBL19641884 0.80 ALOX5 (0.67) ALOX5POLBKDM4EPARP1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3861403-B1 A VISIBILITY CONTROLLING DEVICE CENTRE FOR NANO AND SOFT MATTER SCIENCES (IN) 2026-01-14 — — EP claimed
EP-4613290-A1 TARGETING MOLECULE-CELL COMPLEX AND PREPARATION METHOD THEREFOR TCI GENE INC (TW) 2025-09-10 — — EP claimed
CN-119997986-A Target molecule-cell complex and preparation method thereof 大江基因医学股份有限公司 2025-05-13 — — CN claimed
CN-118834189-A Light-induced fluorescence excitation probe, indazolone compound, and preparation methods and applications thereof 国科大杭州高等研究院 2024-10-25 — — CN claimed
CN-116143602-B Indenone and indazolone derivatives with antioxidant activity, and synthetic method and application thereof 西南大学 2024-10-22 — — CN claimed
WO-2024094131-A1 TARGETING MOLECULE-CELL COMPLEX AND PREPARATION METHOD THEREFOR 大江基因医学股份有限公司 2024-05-10 — — WO claimed
CN-116554104-A Indenone and indazolone derivatives with antioxidant activity, and synthetic method and application thereof 西南大学 2023-08-08 — — CN claimed
CN-116143602-A Indenone and indazolone derivatives with antioxidant activity, and synthetic method and application thereof 西南大学 2023-05-23 — — CN claimed
WO-2022253252-A1 HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS SILEXON BIOTECH CO., LTD. (CN) 2022-12-08 — — WO claimed
EP-4735420-A1 ARYL INDOL-3-YL KETONE AND ARYL INDAZOL-3-YL KETONE INHIBITORS OF KIF18A Volastra Therapeutics, Inc. (US) 2026-05-06 — — EP disclosed
EP-4727548-A1 METHOD OF TREATING CANCER WITH INDOLINE INHIBITORS OF KIF18A Volastra Therapeutics, Inc. (US) 2026-04-22 — — EP disclosed
EP-4705281-A1 COMPOUNDS FOR TREATING CANCER Genesis Molecular AI, Inc. (US) 2026-03-11 — — EP disclosed
CN-118834189-B Light-induced fluorescence excitation probe, indazolone compound, and preparation methods and applications thereof 国科大杭州高等研究院 2026-01-02 — — CN disclosed
CN-118834189-B Light-induced fluorescence excitation probe, indazolone compound, and preparation methods and applications thereof 国科大杭州高等研究院 2026-01-02 — — CN disclosed
CN-114796520-A anti-CD 74 antibody conjugates, compositions comprising anti-CD 74 antibody conjugates, and methods of use of anti-CD 74 antibody conjugates 苏特罗生物制药公司 2022-07-29 — — CN disclosed
CN-114672047-A Preparation method and application of carboxymethyl chitosan hydrogel 佛山科学技术学院 2022-06-28 — — CN disclosed
US-11352330-B2 Phenoxymethyl derivatives HOFFMANN-LA ROCHE INC. (US) 2022-06-07 — — US disclosed
CN-114409563-A Linker for protein labeling and application thereof in biological medicine 中国科学院上海药物研究所 2022-04-29 — — CN disclosed
CN-114315733-A Photoinduced cell covalent labeling fluorescent molecule, preparation method and application thereof 中国科学院上海药物研究所 2022-04-12 — — CN disclosed
US-20220075310-A1 METHOD FOR MANUFACTURING REMOVABLE INFORMATION SHEET RICOH COMPANY, LTD. 2022-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352330-B2 Phenoxymethyl derivatives CNKSR1, RB1, RCOR1 ALOX5 3647/4885POLB 1967/4885KDM4E 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback